stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) Operating cash flow
Scholar Rock Holding Corporation's operating cash flow for fiscal 2025 was −$300.0M, compared with −$200.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$296.8M. Over the past ten years it has ranged from −$300.0M (fiscal 2025) to $24.6M (fiscal 2018) — the current reading is the lowest in ten years. Operating cash flow has fallen for 5 consecutive fiscal years. Scholar Rock Holding Corporation ranks 569th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$300.0M | — |
| FY2024 | −$200.9M | — |
| FY2023 | −$145.2M | — |
| FY2022 | −$132.7M | — |
| FY2021 | −$126.8M | — |
| FY2020 | −$60.3M | — |
| FY2019 | −$63.1M | — |
| FY2018 | $24.6M | — |
| FY2017 | −$21.7M | — |
| FY2016 | −$15.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$70.3M | — |
| Mar 2026 | −$82.1M | — |
| Dec 2025 | −$75.5M | — |
| Sep 2025 | −$68.9M | — |
| 34 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $10.5M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.2M |
| ERAS Erasca, Inc. compare | −$98.0M |
| MANE Veradermics Incorporated compare | −$122.9M |
| KOD Kodiak Sciences Inc. compare | −$158.5M |
| CGON CG Oncology, Inc. compare | −$178.5M |
| SRRK Scholar Rock Holding Corporation | −$296.8M |
| COGT Cogent Biosciences, Inc. compare | −$307.5M |
| IMVT Immunovant, Inc. compare | −$414.3M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement